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To investigate the possible occurrence of human immunodeficiency virus (HIV) or human
T-cell lymphotropic virus, type I (HTLV-I) infections in the United States prior to 1979-1981,
when acquired immune deficiency syndrome (AIDS) was first recognized, we tested sera from
310 pregnant women who participated in the Collaborative Perinatal Project during the period
1959-1964 for HIV and HTLV-I antibody. These samples included sera from 53 pregnant
women who were intravenous drug users. The remainder were from women who had cervical
epithelial abnormalities, who developed cervical carcinomas, who had had children with
erythroblastosis fetalis, who had had children that developed malignant neoplasms early in life, or
normal pregnant women. None of the 310 women had confirmed HIV or HTLV-I antibody. The
rate of false-positive reactions with the HIV enzyme-linked immunosorbent assay (ELISA)
antibody test in these long-frozen samples was similar to that observed in fresh sera.
HIV antibody was detected in homosexual patients with AIDS; HTLV-I antibody was not
detected in any of these sera. HTLV-I antibody was detected in 17 of 20 patients with tropical
spastic paraparesis (TSP) and in two of seven patients with other neurological diseases diagnosed
as transverse myelopathy and multiple sclerosis, and in none of nine normal controls; HIV
antibody was not detected in any of these sera patients. Thus, we conclude that there was no
serological evidence of infection with HIV or HTLV-I in the pregnant women studied; however,
HIV antibody was present in all AIDS patients tested, and HTLV-I antibody was found in the
majority of patients with TSP.
INTRODUCTION
The retrovirus human immunodeficiency virus (HIV) has been associated with
acquired immune deficiency syndrome (AIDS) [1,2]. AIDS was first identified in
1981 and since that time the number of patients has increased dramatically. There
have now been over 30,000 reported cases, more than half of whom have died. In the
569
Abbreviations: AIDS: acquired immune deficiency syndrome HIV ELISA: HIV enzyme-linked immu-
nosorbent assay HIV: human immunodeficiency virus HTLV-I: human T-cell lymphotropic virus, type
I HIV IFA: HIV indirect immunofluorescent assay TSP: tropical spastic paraparesis
Address reprint requests to: David L. Madden, D.V.M., Ph.D., Bldg. 36, Rm 5D06, NIH, Bethesda, MD
20892
Copyright © 1987 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.
MADDEN ET AL.
United States the disease occurs primarily among homosexual and bisexual men.
Other risk groups include drug users, hemophiliacs, transfusion recipients, and small
numbers of heterosexual men, women, and children. In some areas, over 30 percent of
the intravenous drug users have HIV antibody. The origin of the disease remains
controversial. There are some indications that infections occurred in Africa for several
years at least before the disease was recognized in the United States.
The retrovirus human T-cell lymphotropic virus, type I (HTLV-I) has been
associated with adult T-cell leukemia and tropical spastic paraparesis (TSP)
[3,4,5,6,7]. Adult T-cell leukemia associated with HTLV-I was initially identified in
Japan and subsequently in other parts of the world. TSP is a slowly progressive
myelopathy which affects primarily the pyramidal tracts bilaterally and symmetri-
cally, affecting mainly the lower extremities. This disease is manifested by difficult
walking, spasticity, hyperflexion, and extensor plantar response. There is minimal
sensory deficit. TSP occurs primarily in the tropical and subtropical latitudes such as
Jamaica, Columbia, South Africa, and south India.
To study the possibility of the occurrence of HIV and HTLV-I antibody in the
United States before 1981, we examined sera obtained from pregnant women enrolled
in the Collaborative Perinatal Project of the National Institute of Neurological and
Communicative Disorders and Stroke during the period 1959-1964. Included in these
studies were samples from intravenous drug users, women with multiple pregnancies,
women with abnormal children, and normal pregnant women. In addition, to indicate
sensitivity of the serological tests used, we tested specimens from several current
patient groups: homosexual patients with AIDS, homosexual controls without disease,
patients with TSP, and controls.
MATERIALS AND METHODS
Patient Population
The pregnant women included in this study were enrolled in the Collaborative
Perinatal Project of the National Institute of Neurological and Communicative
Disorders and Stroke, NIH. The study population has been well characterized [8,9].
Considerable data are available for health history, socioeconomic level, and ethnic
grouping. Serum samples from over 55,000 pregnant women were collected during
1959-1964. For this study, serum samples from a subgroup of 310 pregnant women
were selected. All samples tested were obtained from women near term. One hundred
patients were selected, without regard to disease status, to represent the major
geographic areas of the United States. An additional 53 patients had a history of
intravenous drug addiction, 35 patients had had ten or more pregnancies, 35 patients
had had babies with erythroblastosis fetalis; 15 patients had advanced carcinoma of
the uterus at delivery, 15 patients developed evidence of abnormal cervical epithelium
during pregnancy, and 21 had had children who developed malignant neoplasm during
the first four years of age. For the latter two groups, 36 matched controls with normal
outcome were included.
The current patient groups studied included 25 patients with AIDS, 25 homosexual
patients with HIV antibody but without clinical signs of disease, and 54 homosexuals
without disease from Los Angeles, California [10,11] as well as 20 patients with
tropical spastic paraparesis (TSP) from the Seychelles Islands and 16 controls, of
whom seven had other neurological diseases and nine were normal.
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TABLE 1
Antibody to HIV and HTLV-I, Pregnant Women, 1959-1964
No. Positive/No. Tested No. Positive/No. Tested
Patient Population HIV HTLV-I
100 random selection 0/100" NTb
53 intravenous drug users 0/53 0/53
35 had ten or more pregnancies 0/35 0/35
35 had babies with erythroblastosis fetalis 0/35 0/35
15 had advanced cervical carcinoma at
delivery 0/15 0/15C
15 developed abnormal cervical
epithelium during pregnancy 0/15 0/15
15 matched normal controls 0/15 0/15
21 had children who developed
malignancies 0/21 0/21
21 matched normal controls 0/21 0/21
0/310 0/210
'Two had initial ELISA-positive reactions.
bNot tested
cOne had initial ELISA-positive reaction.
Serological Tests
The enzyme-linked immunosorbent assay (ELISA) test was used as the initial test to
detect HIV and HTLV-I antibody [12,13]. All ELISA tests were performed using
commercially available reagents. The HIV ELISA reagents were obtained from
Organon Teknika Corp. (Oklahoma City, OK; manufactured by Bionetics Lab
Products, Charleston, SC), or Electronucleonics (ENI) (Columbia, MD). The HTLV-
I ELISA reagents were obtained from the Dupont Company (Billeria, MA; manufac-
tured by Biotech Research Labs, Inc., Rockville, MD). The tests were performed
according to the directions supplied by the manufacturer. The appropriate positive and
negative sera supplied by the manufacturer were used to verify the sensitivity of the
tests. In addition, a panel of our own positive and negative control sera was included
with each set of tests.
Indirect immunofluorescence assay (IFA) was also used for HIV and HTLV-I
antibody determinations [13,14]. The reagents for the IFA were obtained from ENI.
The slides for HIV used the HTLV-IIIb virus in H9 cells and non-infected H9 cells for
the control antigen. For HTLV-I, the slides contained HTLV-I in HUT 102 cells and
non-infected H9 cells for the controls. The tests were performed as recommended by
ENI and appropriate positive and negative sera were included.
The Western blot tests were performed by ENI [14].
RESULTS
The results obtained from testing the serum samples from the pregnant women in
the Collaborative Perinatal Project for HIV and HTLV-I are presented in Table 1.
Only two of the 310 serum samples had ELISA HIV antibody reactivity. The medical
history of these two women was reviewed. Patient 1 had a normal pregnancy with no
significant clinical disease. The child born to this woman developed erythroblastosis
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TABLE 2
Follow-Up Testing of HIV ELISA-Positive Sera from the Collaborative Perinatal Project
Organon ENI IFA IFA
Patient ELISA ELISAb HIVC H9d WBe
I + + + +
2 - + _ _ _
aOrganon Teknika Corp., Oklahoma City, OK
bElectronucleonics, Columbia, MD
CIFA test using HTLV-IIIb infected cells
dIFA test using control H9 cells
'Western blot
fetalis. A prior pregnancy had been uneventful, and a normal child had been born.
Patient 2 had a normal pregnancy with no significant clinical diseases. The child born
to patient 2 was normal. Patient 2 had had 11 previous pregnancies, two of which
terminated in spontaneous abortions. The nine other children were healthy.
The results of retesting these two samples with the Organon and ENI ELISA
reagents as well as the IFA and Western blot studies are presented in Table 2. Serum
from patient 1 gave a positive test reaction in both of the ELISA methods and reacted
in the IFA test with both the HTLV-III virus-infected cells and the H9 control cells; it
was negative in the Western blot test. Therefore it was concluded that this sample was
negative and that the reaction observed in the two ELISA tests and the IFA were
nonspecific. The serum from patient 2 reacted only in the ENI ELISA kit; it was
negative with the Organon ELISA reagents and the IFA test, and the Western blot test
was also negative. Thus, none of the sera collecting during 1959-1964 were HIV
antibody-positive.
Only one of the 210 serum samples from the pregnant women was positive with the
initial HTLV-I ELISA reagents. This sample was from a patient with advanced
carcinoma of the uterus. On subsequent ELISA tests, it was consistently negative.
When tested on the HTLV-I IFA antigen slide and the H9 control cell slide, it was also
negative. Thus, none of the sera collected between 1959-1964 were positive for
HTLV-I antibody.
The results of testing AIDS patients, homosexual controls, TSP patients, and
controls are presented in Table 3. Sera obtained from homosexuals with clinical signs
of AIDS and abnormal T4/T8 ratios were all positive for HIV antibody with both
Organon and ENI HTLV-III ELISA reagents; they were also positive for HIV
antibody with the IFA test and negative with the H9 cell control. Sera from 25
homosexuals had HIV antibody by both of the ELISA tests and the IFA test but no
significant clinical signs of disease; some of them had reversals of T4/T8 ratios.
Homosexuals without clinical signs of disease or abnormal T4/T8 ratios had no HIV
antibody by either of the HIV ELISA methods; the IFA tests were also negative. Sera
from the TSP patients and controls were negative for HIV antibody with both the
ELISA methods and the IFA tests. Seventeen of the 20 TSP patients were positive for
HTLV-I antibody by both the ELISA and IFA test, as were sera from two of the seven
patients with other neurological diseases. These two patients were diagnosed as having
transverse myelopathy and multiple sclerosis. Sera from the nine normal control
patients were negative for HTLV-I antibody. None of the sera from the AIDS patients
or homosexual controls were positive for HTLV-I.
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TABLE 3
Antibody to HIV and HTLV-I Patients with AIDS, Normal Homosexuals,
Patients with Tropical Spastic Paraparesis, and Controls
Patient Population HIV HTLV-I
25 AIDS patients 25/25 0/25
25 HIV-infected patients 25/25 0/25
54 Normal homosexuals 0/54 0/54
20 Tropical spastic paraparesis 0/20 17/20
7 Other neurological disease patients
Syphilitis dementia 0/3 0/3
Peripheral neuropathy 0/1 0/1
Transverse myelopathy 0/1 1/1
Guillain-Barre syndrome 0/1 0/1
Multiple sclerosis 0/1 1/1
9 Normal controls 0/9 0/9
DISCUSSION
The ELISA test for HIV antibody has been licensed for use by blood banks as a
method of screening and eliminating transmission of AIDS by blood and blood
products [15]. Currently, at least seven manufacturers produce kits that are used not
only in blood banks but also in seroepidemiological studies and in determining the
antibody status of individuals. A number of initial false positives are expected;
therefore, initial ELISA-positive tests are repeated in duplicate and, if the repeated
tests are positive, they are confirmed by Western blot or IFA [12,13,14]. In low-risk
populations such as normal blood donor populations, about 0.85 percent of the samples
are positive on the initial ELISA test and about 0.28 percent are positive on repeat
testing.
In our study we found two HIV ELISA antibody-positive samples from pregnant
women during the time period 1959-1964 which were repeatedly positive by at least
one of the tests. One of these samples was positive in IFA with both the HTLV-III
infected and H9 control cells, and the other was IFA-negative. Both were Western
blot-negative. Thus, they were negative for specific HIV antibody. In our study on
these stored sera, about 0.58 percent of the samples were repeat ELISA-positive. This
result is similar to samples expected in low-risk populations. The cause of these repeat
ELISA-positive samples is not known. In one of our samples, it seemed that the false
reading was related to the tissue culture cell antigen in which the virus was grown
[ 14,16]. The cause of the second false ELISA reaction is not clear. Thus, in our study
of a defined population, including drug users, we did not find confirmed evidence for
HIV infection in the United States early in the 1960s.
Our data from a homosexual population is consistent with previous studies
[2,10,1 1]. Homosexuals with clincial AIDS have HIV infection. Those homosexuals
without evidence of clinical disease may or may not have HIV antibody. HTLV-I
antibody was not detected in the homosexual population studied and is not associated
with development of clinical AIDS.
In our study, we found on the intial test one HTLV-I ELISA-positive sample from
the serum of a pregnant woman who had advanced carcinoma of the uterus at delivery.
This sample was not positive on the repeat ELISA or IFA tests. Thus, we did not find
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evidence of confirmed HTLV-I antibody in sera collected between 1959-1964. Our
data indicate that HTLV-I is associated with TSP.
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